Shots:
- Health Canada has approved Keytruda + chemoradiotherapy (CRT) for the treatment of adults with FIGO 2014 Stage III-IVA cervical cancer
- Approval was based on P-III (KEYNOTE-A18/ ENGOT-cx11/GOG-3047) trial assessing Keytruda (200mg, IV, Q3W × 5 cycles) + CRT followed by Keytruda (400mg, IV, Q6W × 15 cycles) vs PBO + CRT in 1060 pts with locally advanced cervical cancer incl. 599 with FIGO 2014 Stage III-IVA
- Trial showed improved PFS & OS in the overall population, with exploratory subgroup analysis indicating that these outcomes were primarily driven by pts with FIGO 2014 Stage III–IVA disease, where Keytruda + CRT improved both PFS & OS
Ref: NewsWire CA| Image: Merck| Press Release
Related News:- Merck Advances MK-8527 in P-III (EXPrESSIVE) Trials to Prevent HIV in Individuals at Risk
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
